EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial

Dimitrios Bourikas, Sami Elmoufti, Jan-Peer Elshoff, Allison Little, Kristy Pucylowski, Brian Moseley, Lieven Lagae

Epilepsy & Behavior · 2025

DOI: 10.1016/j.yebeh.2025.110569 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Dimitrios Bourikas und 6 weiteren Autor:innen. Beteiligte Einrichtung: UCB, Agiou Dimitriou 63, Alimos 17456, Greece. Electronic address: Dimitrios.Bourikas@ucb.com. Hauptthemen laut MEDLINE: Pyrrolidinones, Anticonvulsants, Seizures, Epilepsy, Generalized. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To assess long-term safety, tolerability, and efficacy of adjunctive brivaracetam in children with generalized-onset seizures. METHODS: Subgroup analysis of a Phase 3, open-label trial (N01266/NCT01364597; ≤5 mg/kg/day brivaracetam [maximum 200 mg/day]) in patients aged ≥ 1 month to < 17 years with generalized-onset seizures at core trial entry. Seizure-related outcomes were assessed for patients aged < 2/≥2 years using daily record-card data. Kaplan-Meier-estimated retention and change in Achenbach Child Behavior Checklist (CBCL) scores were assessed post hoc. RESULTS: Of 257 patients receiving brivaracetam, 68 had generalized-onset seizures (50.0 % male; mean age: 6.65 years; median modal brivaracetam dose 3.6 mg/kg/day). Twenty-eight (41.2 %) patients completed the trial; most common reasons for discontinuation (≥10 % patients) were adverse event (22.1 %), lack of efficacy (17.6 %), and withdrawn consent (11.8 %). Kaplan-Meier-estimated retention at 1, 3, and 5 years was 61.8 %, 47.7 %, and 43.3 %, respectively. Sixty-one (89.7 %) patients had treatment-emergent adverse events (serious 25 [36.8 %]). In patients aged < 2/≥2 years (n = 12/n = 33), median percent reduction in 28-day-adjusted total seizure frequency from baseline to end of evaluation was 66.7 %/56.9 %; 50.0 %/60.6 % had ≥ 50 % reduction in all seizures. Mean changes from baseline to last evaluation in Achenbach CBCL 1.5-5 raw syndrome scores (n = 18) were all around 0 (minimal/small amplitude). Mean changes in CBCL 6-18 raw syndrome scores (n = 20) showed small numerical improvements for most syndromes. At last evaluation, most patients (range: 61.1 %-100 %) remained in baseline T-score categories. CONCLUSIONS: Long-term adjunctive brivaracetam was well tolerated and efficacious in children with generalized-onset seizures. Behavior/emotional function were generally stable or slightly improved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrrolidinonesAnticonvulsantsSeizuresEpilepsy, GeneralizedHumansMaleFemaleChildChild, PreschoolAdolescentInfantTreatment OutcomeFollow-Up StudiesDrug Therapy, CombinationKaplan-Meier Estimate

Stichwörter der Autor:innen

Achenbach CBCLAntiseizure medicationBehaviorEfficacyEmotional functioningTolerability

Substanzen

brivaracetamPyrrolidinonesAnticonvulsants

Autor:innen und Institutionen

  • UCB, Agiou Dimitriou 63, Alimos 17456, Greece. Electronic address: Dimitrios.Bourikas@ucb.com.
  • UCB, 4000 Paramount Parkway, Morrisville, NC 27560, United States. Electronic address: Sami.Elmoufti@ucb.com.
  • UCB, Rolf-Schwarz-Schütte Platz 1, 40789 Monheim am Rhein, Germany. Electronic address: Jan-Peer.Elshoff@ucb.com.
  • UCB, 1950 Lake Park Drive SE, Smyrna, GA 30080, United States. Electronic address: little.ae@gmail.com.
  • UCB, 1950 Lake Park Drive SE, Smyrna, GA 30080, United States. Electronic address: Kristy.Pucylowski@ucb.com.
  • UCB, 4000 Paramount Parkway, Morrisville, NC 27560, United States. Electronic address: Brian.Moseley@ucb.com.

Förderung

  • UCB

Zitieren

APA

Bourikas, D., Elmoufti, S., Elshoff, J. P., Little, A., Pucylowski, K., Moseley, B., & Lagae, L. (2025). Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110569

Vancouver

Bourikas D, Elmoufti S, Elshoff JP, Little A, Pucylowski K, Moseley B, et al. Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110569

BibTeX
@article{Bourikas2025,
  author = {Bourikas, Dimitrios and Elmoufti, Sami and Elshoff, Jan-Peer and Little, Allison and Pucylowski, Kristy and Moseley, Brian and Lagae, Lieven},
  title = {Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial},
  journal = {Epilepsy & Behavior},
  year = {2025},
  doi = {10.1016/j.yebeh.2025.110569}
}
Kostenlos starten →